|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Intelligence
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function.
|
29844566 |
2018 |
|
Ataxia
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Nevertheless, only global intellectual abilities and executive functions significantly correlated with the overall severity of ataxia as assessed by the SARA scale, and impaired executive functions alone correlated with performance on several spatio-temporal gait analysis parameters.
|
31637587 |
2020 |
|
Ataxia
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Three paediatric neurologists independently assessed videotaped motor behaviour phenotypically and quantitatively (using the Scale for Assessment and Rating of Ataxia [SARA]).
|
31529709 |
2020 |
|
Cerebellar Ataxia
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Nevertheless, only global intellectual abilities and executive functions significantly correlated with the overall severity of ataxia as assessed by the SARA scale, and impaired executive functions alone correlated with performance on several spatio-temporal gait analysis parameters.
|
31637587 |
2020 |
|
Cerebellar Ataxia
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Three paediatric neurologists independently assessed videotaped motor behaviour phenotypically and quantitatively (using the Scale for Assessment and Rating of Ataxia [SARA]).
|
31529709 |
2020 |
|
Ataxia
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
A cohort of 100 subjects (N = 18-21 in each SCA group, including premanifest mutation carriers; mean score on the Scale for the Assessment and Rating of Ataxia [SARA] <10 for all genotypes, and 22 matched controls) was scanned at 7 Tesla to obtain neurochemical profiles of the cerebellum and brainstem.
|
29575033 |
2018 |
|
Ataxia
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
We determined the severity of ataxia clinically (SARA score) and the pattern of cerebellar involvement by neuroimaging (MRI volumetry and MR spectroscopy).
|
29427835 |
2018 |
|
Cerebellar Ataxia
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
A cohort of 100 subjects (N = 18-21 in each SCA group, including premanifest mutation carriers; mean score on the Scale for the Assessment and Rating of Ataxia [SARA] <10 for all genotypes, and 22 matched controls) was scanned at 7 Tesla to obtain neurochemical profiles of the cerebellum and brainstem.
|
29575033 |
2018 |
|
Cerebellar Ataxia
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
We determined the severity of ataxia clinically (SARA score) and the pattern of cerebellar involvement by neuroimaging (MRI volumetry and MR spectroscopy).
|
29427835 |
2018 |
|
Ataxia
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
ICC values were similar in both EOA subgroups of 'core' and 'comorbid' ataxia (0.92-0.99; ICARS, SARA, and BARS).
|
27767206 |
2017 |
|
Ataxia
|
0.070 |
AlteredExpression
|
phenotype |
BEFREE |
Rater-blinded clinical assessment (Scale for the Assessment and Rating of Ataxia; SARA), individual goal-attainment scoring (GAS), and quantitative movement analysis were performed two weeks before training, immediately prior to training, and after training phases 1 and 2 (intra-individual control design).
|
28365204 |
2017 |
|
Cerebellar Ataxia
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
ICC values were similar in both EOA subgroups of 'core' and 'comorbid' ataxia (0.92-0.99; ICARS, SARA, and BARS).
|
27767206 |
2017 |
|
Cerebellar Ataxia
|
0.070 |
AlteredExpression
|
phenotype |
BEFREE |
Rater-blinded clinical assessment (Scale for the Assessment and Rating of Ataxia; SARA), individual goal-attainment scoring (GAS), and quantitative movement analysis were performed two weeks before training, immediately prior to training, and after training phases 1 and 2 (intra-individual control design).
|
28365204 |
2017 |
|
Ataxia
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Clinical evaluation was done with the ataxia scales SARA and NESSCA.
|
22090366 |
2012 |
|
Cerebellar Ataxia
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Clinical evaluation was done with the ataxia scales SARA and NESSCA.
|
22090366 |
2012 |
|
Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Taken together, we demonstrated that Kindlin-1 promotes CRC progression by recruiting SARA and Smad3 to TβRI and thereby activates TGF-β/Smad3 signaling.
|
27776350 |
2016 |
|
Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
A novel serine protease SNC19 associated with human colorectal cancer.
|
11780337 |
2001 |
|
Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
International comparisons show strong inverse protective associations with starch, NSP (fibre, non-starch polysaccharides) and vegetable intakes, and positive associations with meat consumption in large bowel cancer.
|
9103247 |
1997 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Using the "Cancer Cohort," a national-based cohort (medico-administrative database), all women between the ages of 50 and 74 years and treated in 2014 for incident breast cancer were compared, according to whether their diagnosis was made following a mammogram performed within the framework of the SP (SP group) or outside it (NSP group).
|
31172693 |
2019 |
|
Epilepsy
|
0.020 |
Biomarker
|
disease |
BEFREE |
In this study, we examined the expressions of SARA and level of p-Smad3 in brain tissues of TLE patients using immunohistochemistry and western blot to demonstrate that SARA activation in neurons is sufficient to facilitate TGF- β pathway in patients to regulate epilepsy.
|
30847724 |
2019 |
|
Epilepsy, Temporal Lobe
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Our results indicate that upregulation of SARA and p-Smad3 in cortex neurons might be involved in the development of intractable temporal lobe epilepsy.
|
30847724 |
2019 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
Using the "Cancer Cohort," a national-based cohort (medico-administrative database), all women between the ages of 50 and 74 years and treated in 2014 for incident breast cancer were compared, according to whether their diagnosis was made following a mammogram performed within the framework of the SP (SP group) or outside it (NSP group).
|
31172693 |
2019 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Last, a health services audit for cancer using the WHO SARA tool was undertaken.
|
29120823 |
2017 |
|
Epilepsy
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The expression of SARA and downstream Phospho-Smad3 (p-Smad3) was examined in rats with pilocarpine induced epilepsy.
|
28035691 |
2017 |